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Reconstructive surgery of congenital heart disease (CHD) remains inadequate due to
the inability of prosthetic grafts to match the somatic growth of pediatric patients.
Functionalization of grafts with mesenchymal stem cells (MSCs) may provide a solution.
However, MSCs represent a heterogeneous population characterized by wide diversity
across different tissue sources. Here we investigated the suitability of umbilical cord
pericytes (UCPs) in neonatal vascular engineering. Explant outgrowth followed by
immunomagnetic sorting was used to isolate neural/glial antigen 2 (NG2)+/CD31− UCPs.
Expanded NG2 UCPs showed consistent antigenic phenotype, including expression
of mesenchymal and stemness markers, and high proliferation rate. They could be
induced to a vascular smooth muscle cell-like phenotype after exposure to differentiation
medium, as evidenced by the expression of transgelin and smooth muscle myosin
heavy chain. Analysis of cell monolayers and conditioned medium revealed production
of extracellular matrix proteins and the secretion of major angiocrine factors, which
conferred UCPs with ability to promote endothelial cell migration and tube formation.
Decellularized swine-derived grafts were functionalized using UCPs and cultured under
static and dynamic flow conditions. UCPs were observed to integrate into the outer
layer of the graft and modify the extracellular environment, resulting in improved elasticity
and rupture strain in comparison with acellular grafts. These findings demonstrate that
a homogeneous pericyte-like population can be efficiently isolated and expanded from
human cords and integrated in acellular grafts currently used for repair of CHD. Functional
assays suggest that NG2 UCPs may represent a viable option for neonatal tissue
engineering applications.
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INTRODUCTION
Congenital heart disease (CHD) is the most prevalent congenital
abnormality, affecting∼1% of newborns globally, with incidence
rate seemingly increasing over the last 50 years (1). Although
prognosis has significantly improved, CHD remains one of
the primary causes of perinatal mortality, accounting for over
250,000 deaths in 2017 (2). Complex malformations such as
Tetralogy of Fallot (ToF) often require immediate surgical
correction using a prosthetic graft. Unfortunately, current grafts
have limitations and need to be substituted through repeated
interventions due to pathologic remodeling and failure (3, 4).
In recent years, engineering of prosthetic grafts with
regenerative cells, such as mesenchymal stem cells (MSCs), has
emerged as a potential solution (5, 6). However, MSCs represent a
heterogeneous population characterized by wide diversity across
different tissue sources. Evidence from our group and others have
highlighted the potential advantage of using more homogeneous
perivascular mesenchymal populations, such as microvascular
and adventitial pericytes, for applications of vascular regenerative
medicine (7, 8). Moreover, we demonstrated the feasibility of
reconstructing the pulmonary artery of piglets using grafts
engineered with pericytes immunosorted from cardiac tissue (9).
Cardiac pericytes attract endothelial cells (ECs) and produce
extracellular matrix (ECM) proteins, which may help to alleviate
the limitations of the acellular technology. Nonetheless, the
use of heart-derived cells is only compatible with a two-stage
intervention—an invasive harvesting followed by implantation—
with risks superior to an immediate correction approach (10–
12). An alternative cell population from an easily accessible
tissue, such as the umbilical cord, would therefore offer obvious
advantages over cardiac pericytes.
Perivascular progenitor cells characterized by a
myofibroblastic mesenchymal phenotype have been expanded
from pre-term umbilical cords using a dissection/culture
selection procedure; however, key stemness features were lost
when applying the same method to isolate perivascular cells
from full-term cords (13). Immunomagnetic sorting provides a
more refined technique to isolate target cells from heterogeneous
mixtures. To the best of our knowledge, antigenically pure
pericytes from umbilical cord of full-term neonates have never
been tested for graft engineering.
The present study established a novel method for isolation
and expansion of umbilical cord pericytes (UCPs) expressing
the neural/glial antigen (NG2). We have characterized the
antigenic and secretory phenotype of NG2 UCPs and their
ability to differentiate along the vascular smooth muscle cell
(VSMC) lineage and modulate angiogenesis in vitro. Moreover,
we showed that NG2 UCPs can engraft onto a clinically available
conduit made of small intestinal submucosa extracellular matrix




Full-term human umbilical cord samples were obtained with
informed consent from St. Michael’s Hospital, Bristol, UK.
Their use throughout the project was approved by the
Southwest Research Ethics Committee (license 11/HO107/4)
and conformed to the principles outlined in the Declaration
of Helsinki.
Cell Isolation and Culture
Initial isolation of pericytes from human umbilical cord samples
was attempted using a protocol previously developed by our
group for the isolation of saphenous vein and cardiac pericytes
(14, 15). Briefly, umbilical cord sections were enzymatically
digested and cell suspensions immunomagnetically sorted using
anti-CD31 and anti-CD34 microbeads (Miltenyi Biotech).
CD31−/CD34+ cells were cultured in endothelial growth
medium 2 (EGM-2; Promocell) on tissue culture plastic pre-
coated with 0.01% (w/v) gelatin (Sigma-Aldrich) and 10 mg/ml
fibronectin (Sigma-Aldrich) and maintained at 37◦C (5% CO2)
(14, 15).
An alternative method for isolation of UCPs was developed,
which utilized explant outgrowth instead of enzymatic digestion
(Figure 1). The umbilical vessels were extracted from the
cord and Wharton’s Jelly removed. Sections (1–3 mm2) of
the umbilical artery were placed in a flask and cultured in
EGM-2. After 7–10 days in culture, colonies of cells were
observed migrating out from the explants. The explant tissue was
removed using sterile forceps, and the migrated cells harvested.
This heterogenous cell population was then purified using
immunomagnetic selection. Briefly, cells were incubated with
anti-CD31 microbeads in column buffer, comprising of 0.5%
(w/v) bovine serum albumin (BSA; Sigma-Aldrich) and 2mM
pH8 EDTA (Ambion), according to manufacturer’s instructions.
The suspension was filtered through a magnetic column, keeping
the CD31− cell population, and the selection process was
repeated using anti-NG2 beads (Miltenyi Biotech), retaining the
NG2+ pericyte population. The acquired cell population was
then cultured in EGM-2 on pre-coated tissue culture plastic as
detailed above and maintained a 37◦C (5% CO2).
Human Wharton’s Jelly MSCs (Promocell) were used for
comparative studies with isolated pericytes due to their
frequent application in tissue engineering studies (5, 6). MSCs
were expanded in mesenchymal stem cell growth medium 2
(Promocell). Human umbilical vein endothelial cells (HUVECs;
Lonza) were cultured in EGM-2 on 0.5% (w/v) gelatin coated
surfaces. Adult normal human dermal fibroblasts (NHDF; Lonza)
were cultured in fibroblast growth medium 2 (Lonza).
All cells were used for experimentation between passages 3
and 7.
Immunohistochemistry
Tissue samples were collected and fixed in 4% (w/v) buffered
paraformaldehyde (PFA; Sigma-Aldrich) for 24 h at 4◦C. Samples
were then washed in phosphate buffered saline (PBS), placed
in 30% (w/v) sucrose for 24 h at 4◦C, and embedded in
optimal cutting temperature compound (Tissue-Tek R© O.C.T.,
from VWR). Eight-micron sections were cut using a CryoStar
NX50 cryostat (Thermo Fisher Scientific) set to −20◦C, and
mounted onto Superfrost Plus slides (Thermo Fisher Scientific).
Slides were hydrated in PBS for 10min and permeabilized
with 0.01% Triton-X100 (Sigma-Aldrich) in PBS for 10min at
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FIGURE 1 | Protocol for isolation of NG2 UCPs. Umbilical vessels were extracted from the cord and the Wharton’s Jelly removed. 1–3 mm2 sections of the umbilical
artery were placed in a flask and cultured in EGM-2. After 7–10 days, the tissue sections were removed, and migrated cells were collected. The cells were sorted to
obtain an NG2+/CD31− pericyte population using immunomagnetic selection. The purified cell population was cultured in EGM-2 and expanded for further
experimentation.
20◦C. Non-specific binding sites were blocked using 5% fetal
bovine serum (FBS) in PBS for 30min at 20◦C. Slides were
triple stained with CD31, CD34, and NG2 primary antibodies
(Supplementary Table 1). Cells were incubated with appropriate
secondary antibodies (Supplementary Table 2) for 1 h at 20◦C,
before counterstaining with DAPI and imaging with a Zeiss
Observer.Z1 microscope.
Expansion Capacity and Viability
Cells were seeded in a 6-well plate at a density of 3,000 cells/cm2.
They were detached on day 4, 5, 6, and 7, and live cells
counted after Trypan Blue Solution (Thermo Fisher Scientific)
exclusion staining. Doubling time was determined using a growth
curve and viability was calculated from the number of live and
dead cells.
Immunocytochemistry
Adherent cells were fixed with 4% PFA for 10min and
blocked with 5% FBS in PBS. For detection of intracellular
or transmembrane antigens, cells were permeabilized prior to
blocking using 0.1% Triton-X100 (Sigma-Aldrich) in PBS for
10min at 4◦C. Primary antibodies were incubated overnight
at 4◦C (Supplementary Table 1). Cells were incubated with
appropriate secondary antibodies (Supplementary Table 2) for
1 h at 20◦C, before counterstaining with DAPI and imaging with
a Zeiss Observer.Z1 microscope.
Flow Cytometry
Cultured cells were harvested and resuspended in staining
buffer comprising of 1% (w/v) BSA and 1mM EDTA pH8
in PBS prior to blocking with Human Fc Receptor Binding
Inhibitor. Tubes were prepared with 200,000 cells incubated
with 100 µl antibodies in staining buffer at 4◦C in the
dark for 30min (Supplementary Table 3). Cells were labeled
using Zombie NIRTM viability dye (BioLegend) and dead cells
were excluded. Analysis was completed using a NovoCyte
Flow Cytometer System (ACE Bioscience) and FlowJo software
package. Representative raw histogram data is demonstrated in
Supplementary Figure 1.
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Secretome Characterization
Cell conditioned medium (CM) was collected from NG2 UCPs
and MSCs, which were cultured for 48 h in serum/serum and
vascular endothelial growth factor (VEGF)-free EGM-2 under
culture normoxia (20% O2) or hypoxia (2% O2). This medium
was centrifuged to remove detached cells and stored at −80◦C
until analysis by ELISA, angiogenesis assay or migration assay.
The quantities of angiopoietin-1 (ANGPT-1), Angiopoietin-2
(ANGPT-2), stromal derived factor-1 (SDF-1), VEGF-A, and
monocyte chemoattractant protein-1 (MCP-1) were determined
in CM using specific anti-human ELISA kits (all from R&D
Systems) following manufacturer’s instructions. Values were
normalized by the conditioning time and number of cells
at harvest.
Angiogenesis Assay
The pro-angiogenic potential of cells was evaluated using a
co-culture angiogenesis assay as previously described (16, 17).
Two different approaches were utilized to investigate if NG2
UCPs pro-angiogenic potential results from their secretome
or physical cell-to-cell crosstalk. Briefly, NHDFs were seeded
(10,000 cell/cm2) in either a 96-well plate [CM (secretome)
analysis] or 24-well plate (cell-to-cell contact analysis) and
cultured over 5 days until a confluent monolayer had formed.
HUVECs were then seeded (10,000 cell/cm2) in either CM or
control medium (serum/VEGF-free EGM-2) (for CM analysis),
or co-seeded with either NG2 UCPs or MSCs (pre-labeled
with DsRED using lentiviral transduction; 2,500 cell/cm2) in
EBM-2 (10% FBS) (for cell-to-cell contact analysis). Following
incubation for 6 days, with medium refreshed every 2 days, cells
were fixed with 4% PFA and networks were stained with anti-
CD31 antibody (1:200; R&D Systems). Images were acquired
using a Zeiss Axio Observer.Z1 microscope and analyzed
using ImageJ.
Differentiation to Vascular Smooth Muscle
Cells
Differentiation of NG2 UCPs was achieved by incubation with
transforming growth factor beta (TGF-β). Cells were cultured
in complete EGM-2 until 80% confluent before changing to
the differentiation medium, consisting of EGM-2 supplemented
with a 2 ng/ml TGF-β1 (Peprotech) dosage, as previously
reported (18). EGF and FGF were removed due to their
attenuation of TGF-β activity (19). After 15 days incubation
with the differentiation medium, replenished every 3 days, cells
were harvested for analysis. Undifferentiated cells cultured in




Total RNA was extracted from cells using a miRNeasy Mini
Kit (Qiagen) and reverse transcribed into first-strand cDNA
using a High Capacity RNA-to-cDNA Kit (Life Technologies)
according to manufacturer’s instructions. Relative mRNA
expression was determined by quantitative PCR (qPCR) using
TaqManTM Universal Master Mix II with UNG (Thermo Fisher
Scientific) and a QuantStudio 6 Flex Real-Time PCR system
(Applied Biosystems). A list of probes used can be found
in Supplementary Table 4. Analysis was performed using the
2−11Ct (Livak) method and results normalized to internal
housekeeping control gene Ubiquitin C (UBC). A no template
control (NTC) was included for analysis.
Western Blot
Cell lysates were collected in RIPA buffer (Life Technologies)
supplemented with 1/100 (v/v) protease inhibitors (Sigma-
Aldrich) and 1/50 (v/v) phosphatase inhibitors (Sigma-Aldrich).
Protein concentration was determined using Pierce BCA Protein
Assay (Thermo Fisher Scientific). Protein samples (10 or 20 µg)
were resolved in 8–10% SDS-PAGE gels at 120V for 90min and
transferred onto 0.22µm pore size polyvinylidene difluoride
(PVDF) membranes (GE Healthcare) using a wet system set to
0.25A for 60–75min. Membranes were blocked in 5% non-fat
milk in 100mM Tris, 150mM NaCl, 0.05% Tween-20 for 1 h at
20◦C before incubating with primary antibodies at 4◦C overnight
(Supplementary Table 1). Appropriate ECL-HRP-conjugated
secondary antibodies (Supplementary Table 2) were applied to
the membranes for 1 h at 20◦C and proteins were detected by
enhanced chemiluminescence (ECL) using AmershamTM ECL
Reagent (GE Healthcare). A BioRad ChemiDoc MP was used
to image the protein bands, which were then semi-quantified
by densitometry analysis using ImageJ and normalized to
β-Tubulin loading control. Representative western blot images
are demonstrated in Supplementary Figure 2.
Contraction Assay
The contractile properties of differentiated and undifferentiated
cells were assessed using a collagen gel contraction assay.
Collagen gels (2 mg/ml) were prepared in a 24-well plate (250
µl/cm2) using Rat Tail Collagen I (Thermo Fisher Scientific)
according to manufacturer’s instructions. Cells (50,000/cm2)
were seeded in the gel, which was left to polymerize for 1 h
at 37◦C/5% CO2 before the addition of the differentiation
medium or control medium and incubation for 24 h. After 24 h
incubation, cell contraction was assessed using fresh medium
supplemented with vasoconstrictor endothelin-1 (0.1 µM, Sigma
Aldrich) with or without the myosin ATPase inhibitor 2,3-
butanedione monoxime (10 mM, BDM; cell Biolabs). Gels were
left for a further 1 h before releasing and conditioning for
an additional 24 h. Contraction was quantified using ImageJ
by measuring the change in gel area over the course of
the experiment.
Scratch Wound Migration Assay
Confluent HUVEC monolayers were seeded in 0.5% gelatin-
coated 96 well-plates (15,000 cells/cm2) in EGM-2. A scratch was
made using a 10 µl pipette tip. HUVECs were then incubated
for 12 h with CM or control medium, which were supplemented
with 2mM hydroxyurea (Sigma-Aldrich) to inhibit proliferation.
HUVECs were imaged at 0 and 12 h using a Leica DMi1 inverted
microscope and the scratch area quantified using ImageJ.
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ECM Production
To evaluate the cellular production of ECM, the elastin
and collagen content of confluent cell monolayers was
quantified. Cells were seeded in a 6-well plate (20,000 cells/cm2)
and conditioned in 2mL EGM-2. After 3 and 5 days of
culture, monolayers and CM were processed for elastin and
collagen using a FastinTM Elastin assay or SircolTM collagen
colorimetric assays (Biocolor) according to manufacturer’s
instructions. Content was quantified using a GloMax Discover
Microplate Reader.
The presence of extracellular proteins was also assessed in
decellurized matrix. Briefly, cells were seeded in 96-well plates
(20,000 cells/cm2) and confluent monolayers decellurized by
incubating cells with cold 1mM EDTA pH8 prepared in PBS for
24 h at 4◦C, as described by Pattabhi et al. (20). This process
was repeated until all cells were removed, and collagen and
fibronectin content was analyzed using immunocytochemistry
(Supplementary Table 1).
ECM Degradation
To assess the ability of cells to degrade the ECM, cell
lysates and CM were screened for the presence of active
matrix metalloproteinases (MMPs). Briefly, 500,000 cells
were seeded in a T25 culture flask (20,000 cells/cm2) and
grown until confluent. Once cells became confluent, the
medium was changed and cells were conditioned for 48 h.
CM and cell lysate were harvested and analyzed using
a Human MMP Antibody Array-Membrane-ab134004
(abcam) according to manufacturer’s instructions. A BioRad
ChemiDoc MP was used to image the membranes, which
were semi-quantified using ImageJ and normalized to the
membrane positive control. Results were normalized to
either total protein or total CM volume as appropriate.
Representative array membrane images are demonstrated in
Supplementary Figure 3. Cell lysates and CMwere also analyzed
for collagenase activity using a fluorometric Collagenase
(Collagen Degradation/Zymography) Assay Kit-ab234624,
according to manufacturer’s instructions. Total intracellular
and extracellular collagenase activity was calculated by scaling
measurements according to total protein and CM volume per
T25 culture flask.
Graft Production and Analysis
40 × 30mm pieces of CorMatrix (CorMatrix Cardiovascular)
were cut and positioned in sterile crowns before priming for
24 h in EGM-2 at 37◦C/5% CO2. NG2 UCPs were then seeded
at a density of 20,000/cm2 and cultured in fresh medium
for a further 5 days under static conditions. Samples were
then either analyzed directly or prepared for an additional
7 days dynamic conditioning. For preparation of dynamic
conditioning, the pieces of CorMatrix were stitched into the
shape of a conduit, with the pericytes facing the external
abluminal side of the conduit. The bioreactor system was set
up consisting of a Masterflex L/S digital 07528-20 peristaltic
pump, tubing and 3DCulture Pro bioreactor chambers. The
conduit was then positioned into the bioreactor chamber in
fresh EGM-2 and conditioned for a further 7 days (flow rate
24 ml/min). The conduits were then analyzed using the assays
described below.
For histological analysis, conduit sections were embedded
and probed with αSMA, NG2, or vimentin as detailed
in immunohistochemistry method using antibodies listed in
Supplementary Tables 1, 2. Hematoxylin and Eosin (H&E),
Verhoef ’s van Geison (EVG), and Mallory’s trichrome staining
were completed to visualize the structure, elastin and collagen
content using a Shandon Varistan 24-4 slide stainer (Thermo
Fisher Scientific). Images were acquired using a Zeiss Axio
Observer.Z1 microscope.
Cell proliferation was calculated by probing with marker
of proliferation Ki-67 (1:100; DAKO) followed by incubation
with goat anti-mouse Alexa fluor 488 (Life Technologies) and
counterstained with DAPI as per immunocytochemistry method.
Proliferation and density of cells was calculated by counting
the number of DAPI positive and Ki-67 positive cells. Viability
was analyzed using a LIVE/DEADTM Viability/Cytoxicity
Kit (Thermo Fisher Scientific) according to manufacturer’s
instructions. Cell-seeded scaffolds were counterstained using
Hoechst (1:1,000, 10min; Thermo Fisher Scientific). Viability
was calculated by counting the proportion of live to dead
cells. Presence of soluble collagen in medium collected after
static and dynamic conditioning was assessed using a human
Pro-Collagen I alpha 1 ELISA kit (R&D Systems) as per
manufacturer’s instructions. Results were normalized by
conditioning time.
For mechanical analysis, 5 × 20mm sections were harvested
from the graft and stretched lengthwise using an Instron 3343
tensile machine (Illinois Tool Works Inc), set at 10 mm/min.
The exact area and length of each section was measured using
Vernier calipers, and a stress-strain curve plotted to calculate the
Young’s modulus and rupture strain. Tests were carried out at
37◦C in PBS.
Unseeded controls were included for comparison in all stages
of graft production and analysis.
Statistics
Statistical analysis was performed using GraphPad Prism
software. Differences between 2 experimental groups were
assessed using student’s t-test. Differences between more than 2
groups were evaluated using one or two-way analysis of variance
(ANOVA), followed by Sidak’s post-hoc test or Tukey’s post-hoc
test. All data are presented as mean± standard error of the mean
(SEM), and p < 0.05 was considered statistically significant.
RESULTS
Isolation and Expansion of Pericytes From
Umbilical Cord
The first objective of this study was to determine if pericytes
could be separated from human umbilical cords using
an immunomagnetic beads sorting protocol previously
established for extraction of CD31−/CD34+ pericytes
from saphenous vein and cardiac tissue (14, 15). Using
this method, a total of 11 umbilical cord isolations were
attempted, however only one viable cell line of CD34+ pericytes
Frontiers in Cardiovascular Medicine | www.frontiersin.org 5 January 2021 | Volume 7 | Article 609980
Cathery et al. Cord Pericytes and Graft Engineering
FIGURE 2 | Isolation and expansion of umbilical cord pericytes. (A) Successful and unsuccessful cell isolations from the umbilical cord using two immunomagnetic
sorting methods based on NG2 and CD34 antigens. The percentage above each column indicates the efficiency of the isolation protocol. (B) Immunohistochemical
staining of umbilical artery. DAPI, blue; CD31, white; CD34, red; and NG2, green. Inserts in (i, ii) show NG2 positive pericytes negative for CD31 and CD34. Insert III
shows CD31 and CD34 expression is restricted to the endothelial layer in the lumen. (C) Morphology of NG2 UCPs. (D) Doubling time in culture, calculated from cell
growth curve. (E) Viability analysis of cells in culture. Data represent means (±S.E.M). MSCs and NG2 UCPs, n = 3 and 6 biological replicates, respectively.
(CD34 UCPs) was successfully expanded, resulting in an
isolation efficiency of just 9.1% (Figure 2A). To improve
the isolation of pericytes from umbilical cord, an alternative
methodology was designed, which incorporated explant
outgrowth from cultured umbilical artery, followed by an
immunomagnetic selection of CD31−/NG2+ cells, as detailed
in Methods. A total of 9 isolations were attempted, resulting
in eight viable NG2+ umbilical cord pericyte (NG2 UCP)
populations (Figure 2A). Immunohistochemical analysis of
the umbilical cord confirmed no CD31−/CD34+ pericytes
were present within the tissue; however, only sporadic
staining of NG2 UCPs was detected (Figure 2B). These
data indicate that the native antigenic characteristics of bona
fide perivascular cord pericytes differ from that of other
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FIGURE 3 | Phenotypic characterization of NG2 UCPs. (A) Immunocytochemical staining of NG2 UCPs showing expression of CD146, NG2, vimentin, cardiac
transcriptional factor GATA-binding protein 4 (GATA4), transcription factor NANOG, octamer-binding transcription factor 4 (OCT4), and sex-determining region Y-box 2
(SOX2). NG2 UCPs lack expression of endothelial factors CD31, CD34 and vascular endothelial cadherin (VE-Cadherin). (B) Summary of the expression profile
obtained using flow cytometry. PDGFR-β, platelet-derived growth factor receptor beta. Data represent means (±S.E.M). MSCs and NG2 UCPs, n = 5 and 7 biological
replicates, respectively. **p < 0.01 and ****p < 0.0001.
tissue sources, thus requiring substantial modification of the
isolation protocol.
Cultured NG2 UCPs displayed a spindle-shaped morphology,
typical of pericytes (Figure 2C). The expansion capacity of NG2
UCPs was similar to that of cord MSCs, with a population
doubling time of 50.9 ± 4.7 and 57.9 ± 6.7 h, respectively
(Figure 2D). As a result of the high initial yield of cells following
isolation, we could expand >10 million NG2 UCPs by passage 5
within a 6-week period. The viability of cells also remained high
throughout culture and was not significantly different between
NG2 UCPs and MSCs (Figure 2E).
Antigenic Characteristics of NG2 UCPs
To confirm that the isolated cell product represented a pericyte
phenotype, an immunocytochemical analysis of NG2 UCPs was
completed using an array of antigenic markers (Figure 3A).
Cultured cells displayed absence of endothelial cell markers
CD31, CD34, and vascular endothelial cadherin (VE-Cadherin)
and high expression of pericyte associated markers such as
CD146, NG2, and vimentin (8). Furthermore, cells expressed the
stemness markers GATA-binding protein 4 (GATA4), homeobox
protein NANOG, octamer-binding transcription factor 4 (OCT4)
and sex determining region Y-box 2 (SOX2).
To verify that the new isolation protocol produced a consistent
homogenous pericyte population, flow cytometry was utilized
for further characterization. This confirmed that <5% of
immunomagnetic bead sorted NG2 UCP populations expressed
endothelial markers CD31 and CD34 or hematopoietic marker
CD45 (Figure 3B). Conversely, more than 95% of donor cells
displayed mesenchymal markers CD105, CD73, CD90, and
CD44, in association with NG2 and platelet derived growth factor
receptor beta (PDGFR-β), both >70%. Moreover, only 30% cells
were positive for CD146. This antigenic profile was consistent
between cell donors and corroborated previous studies which
demonstrated in situ perivascular expression of mesenchymal
markers CD105, CD90, and CD44, but absence of endothelial
marker CD34 (21). The profile of NG2 UCPs resembled that
of MSCs except for significantly higher expression of NG2 and
Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 January 2021 | Volume 7 | Article 609980
Cathery et al. Cord Pericytes and Graft Engineering
FIGURE 4 | Analysis of NG2 UCP capacity to differentiate toward a contractile vascular smooth muscle-like phenotype. (A–D) Fold change in mRNA levels of VSMC
markers after differentiation vs. undifferentiated (control). ACTA2, αSMA; CNN1, Calponin; TAGLN, Transgelin; MYH11, SM-MHC. (E–H) Fold change in protein levels
of VSMC markers after differentiation protocol. For (A–H), data represent means (±S.E.M). MSCs and NG2 UCPs, n = 3 and 5 biological replicates, respectively;
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (I) Immunocytochemical staining of VSMC markers at day 0 (undifferentiated) and day 15 (differentiated). (J) Gel
contraction in differentiated and undifferentiated NG2 UCPs after activation with endothelin-1 in the presence or absence of BDM. Data represent means (±S.E.M) of
n = 5 biological replicates. ++p < 0.01.
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FIGURE 5 | Characterization of the NG2 UCP secretome. (A–F) Analysis of
cell-secreted factors in cell-conditioned media, normalized for the volume of
the collected supernatant, time of incubation and cell number. ANGPT-1,
angiopoietin 1; ANGPT-2, angiopoietin; SDF-1, stromal derived factor 1;
VEGF-A, vascular endothelial growth factor A; HGF, hepatocyte growth factor;
MCP-1, monocyte chemoattractant protein 1. Data represent means
(±S.E.M). MSCs n = 3, NG2 UCPs n = 6; */+p < 0.05 and **/++p < 0.01.
*represents differences between hypoxia and normoxia, +represents
differences between cell types.
PDGFR-β in the former. We confirmed that this difference in
expression was not due to the effect of culture media as MSCs
that were cultured in EGM-2 demonstrated no difference in
marker expression to those that were cultured in MSC medium
(Supplementary Figure 2).
Together these data indicate that the new isolation protocol
provides a consistently homogenous pericytes-like cell product.
VSMC Differentiation and Contractile
Capacity of NG2 UCPs
To evaluate if NG2 UCPs could form functional smooth muscle-
like tissue, cells were exposed to medium containing TGF-
β to stimulate differentiation into VSMCs. Differentiated and
undifferentiated NG2 UCPs were screened for an array of
antigenic markers, which are used to indicate the maturity
of the VSMC phenotype (ranging from a synthetic to a
mature contractile phenotype). After 15 days exposure to the
differentiation medium, NG2 UCP mRNA levels of all antigenic
markers were upregulated, although MYH11 displayed the
only significant increase (Figures 4A–D). In comparison, MSCs
demonstrated a significantly greater fold change in ACTA2
and TAGLN. Interestingly, at the protein level, differentiated
NG2 UCPs demonstrated significant upregulation in all VSMC
associated markers, including large increases in αSMA (>6-fold),
calponin (>20-fold), and transgelin (>6-fold) (Figures 4E–H).
Moreover, detection of SM-MHC at both mRNA and protein
levels suggests differentiation toward a specific VSMC phenotype
rather than a myofibroblastic phenotype. MSCs demonstrated
comparable modulations in αSMA, transgelin and SM-MHC, but
less than half the increase in calponin. Figure 4I confirmed the
upregulation of VSMC associated markers. No VSMC marker
expression was observed in the undifferentiated state, however,
differentiated NG2 UCPs acquired the expression of contractile
markers αSMA and calponin, along with a modest upregulation
in VSMC specific contractile marker transgelin.
The contractile ability of differentiated and undifferentiated
NG2 UCPs was assessed to identify if the change in the
antigenic phenotype corresponded to functional readouts. After
stimulation with endothelin-1, NG2 UCPs showed contraction,
more evidently after differentiation (58.9 vs. 47.7% in the
undifferentiated state), with this effect being inhibited by BDM,
an excitation-uncoupling agent (Figure 4J).
These data indicate that NG2 UCPs have native contractile
properties, as seen classically in pericytes, with this property
being increased with the acquisition of VSMC antigens during
forced differentiation.
Endothelium Supporting Properties of NG2
UCPs
Endothelial cell coverage is essential for graft maturation
and reduction of thrombotic complications, whilst graft
neovascularization should supply the tissue with oxygen and
nutrients. NG2 UCPs may facilitate both processes through
the release of factors that attract endothelial cells and promote
angiogenesis. To test this, the CM collected with cells under
normoxic or hypoxic conditions was analyzed for an array of
factors (Figures 5A–F). NG2 UCPs secreted different angiocrine
factors, some of which showed significant modulation by
hypoxia (increase: VEGF-A and reduction: ANGPT-1 and
MCP-1). After normalization for the number of cells, NG2
UCPs showed a superior secretory capacity compared with
MSCs, except for ANGPT-1, which was higher in MSCs, and
ANGPT-2, which was secreted in negligible amounts by both
cell types.
The ability of NG2 UCPs to stimulate the formation of
endothelial capillary-like networks was assessed using the UCP-
derived CM and a 3D co-culture assay. An induction in
cumulative tube length was observed using the NG2 UCP-
derived CM, particularly the medium collected under hypoxic
conditions, which was superior to that of MSC (Figures 6A,B).
Next, the direct angiogenic influence was investigated by seeding
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FIGURE 6 | Analysis of NG2 UCP angiogenic potential. (A) Representative images of endothelial tube network formation after incubation with normoxic or hypoxic
CM. (B) Cumulative tube network using normoxic and hypoxic CM. Note that basal medium control resulted in no network formation. For clarity, control has been
omitted, however, a significant increase from control is represented directly above NG2 UCP hypoxia column. Data represent means (±S.E.M). MSCs and NG2 UCPs,
n = 3 and 6 biological replicates, respectively. */+p < 0.05 and **p < 0.01. *represents differences between hypoxia and normoxia, + represents differences between
cell types. (C) Representative images of endothelial tube network formation with the inclusion of red labeled NG2 UCPs or MSCs in the endothelial cell-fibroblast
co-culture. (D) Fold change in cumulative tube length vs. endothelial cell-fibroblast only control. (E) Fold change in branches per field vs. endothelial cell-fibroblast only
control. (F) Fold change in branch thickness vs. endothelial cell-fibroblast only control. (G) Average distance of cell to branch. (H) Average number of cells per field of
view. For (D–H), data represent means (±S.E.M) MSCs and NG2 UCP, n = 4 and 6 biological replicates, respectively. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001. (I) Representative scratch-wound migration assay images at 0 and 12 h. (J) Summary of fold change in migration vs. control. Data represent means (±S.E.M)
n = 3 biological replicates. *p < 0.05.
NG2 UCPs or MSCs together with HUVEC in the co-culture
assay (Figure 6C). In accordance with the results from CM,
NG2 UCPs significantly increased the tube length in comparison
with MSCs (Figure 6D). Both NG2 UCPs and MSCs induced
a significant increase in average branches per field and branch
thickness (Figures 6E,F). Finally, NG2 UCPs demonstrated a
close association with HUVECs as evidenced by their average
distance to network branch, which was shorter than that of
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FIGURE 7 | NG2 UCPs produce ECM proteins. (A) Quantification of elastin in confluent cell monolayers. (B) Quantification of pepsin acid-soluble collagen in confluent
cell monolayers and CM. (C) Quantification of insoluble collagen in confluent cell monolayers. For (A–C), data represent means (±S.E.M). MSCs and NG2 UCPs, n =
2 and 6 biological replicates, respectively. */+p < 0.05 and **/++p < 0.01. * represents differences between cell types, + represents differences between time points.
(D) Presence of extracellular proteins collagen and fibronectin in decellularized monolayers. (E) Relative MMP levels in NG2 UCP lysate and CM. Data represent
means (±S.E.M), n = 4 biological replicates; *p < 0.05 and ****p < 0.0001. (F) Total intracellular (total protein) and extracellular (CM) collagenase activity in NG2 UCPs
and MSCs per T25 culture flask. Data represent means (±S.E.M). MSCs and NG2 UCPs, n = 4 and 6 biological replicates, respectively. */+p < 0.05 and ***/+++p <
0.001. * represents differences between cell types, + represents differences between intracellular and extracellular activity.
MSCs (Figure 6G). To confirm the angiogenic effect was not
due to increased proliferation of NG2 UCPs, the number of
cells per field of view was counted. Although the average
number of NG2 UCPs was slightly greater than MSCs (69.2
NG2 UCPs vs. 60.9 MSCs), this difference was not significant
(Figure 6H).
Next, using a scratch wound assay, we assessed if NG2
UCPs may accelerate HUVEC migration. We found that ECs
incubated with NG2 UCP CM migrated four times farther than
HUVECs incubated with either unconditioned medium or MSC
CM (Figures 6I,J).
Ability of NG2 UCPs to Remodel the
Extracellular Environment
We next investigated the capacity of NG2 UCPs to produce
ECMproteins andmatrix metalloprotease (MMP) when cultured
as confluent cell monolayers. Elastin content doubled in UCPs
between days 3 and 5, and to a lesser extent in MSCs
(Figure 7A). A similar pattern was observed regarding soluble
collagen quantified in monolayers and CM. However, the initial
superiority of UCPs vs. MSCs was lost at 5 days (Figure 7B).
Likewise, NG2 UCPs produced more insoluble collagen at
3 days but were similar to MSCs at 5 days (Figure 7C).
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Immunocytochemical staining for collagen and fibronectin in
decellularized monolayers also confirmed NG2 UCPs secrete
extracellular proteins (Figure 7D). The presence of MMPs in
NG2 UCPs was visualized using an array membrane. In contrast
to tissue inhibitors of matrix metalloproteinases (TIMPs), only
low levels of MMPs were detected in cell lysates and CM
(Figure 7E). The exception to this was MMP-1, which was
highly secreted into medium. In line with these results, the
extracellular collagenase activity in CM was significantly higher
than intracellular activity assessed in the cell lysate, accounting
for 97% of the active collagenases (Figure 7F). Furthermore, the
extracellular collagenase activity of NG2 UCPs was significantly
higher than that of MSCs.
Generation and Analysis of NG2 UCP
Engineered Grafts
To assess the feasibility of using NG2 UCPs to create a biological
graft, cells were seeded on a CorMatrix scaffold at a density
of 20,000 cells/cm2. The graft was then left in static conditions
for 5 days and either analyzed immediately or shaped into a
conduit and conditioned for a further 7 days in a flow bioreactor
(Supplementary Figure 5). Calcein AM-ethidium homodimer-
1 viability staining demonstrated successful attachment of cells
to the CorMatrix scaffold (Figures 8A,B). After 7 days dynamic
conditioning, the cells were more confluent and aligned in a
uniform direction. Cell viability after both static and dynamic
conditioning was >75%, however, there was a significant drop in
viability after dynamic conditioning (Figure 8C). On average, the
cell density increased 2-fold after a 7-day dynamic conditioning,
however, the variation between donor cell lines meant this
change was not significant (Figure 8D). There was a modest
reduction in the number of Ki67 positive cells after dynamic
conditioning (Figure 8E). Immunohistochemical analysis of the
grafts demonstrated the development of a multi-cell layer on
top of the CorMatrix, with cells retaining expression of the
pericyte associated markers NG2 and vimentin (Figure 8F). The
absence of αSMA was interpreted as the lack of spontaneous
differentiation of engrafted cells toward a contractile phenotype.
As expected, the control unseeded grafts had no cells nor NG2,
Vimentin or αSMA expression.
Finally, H&E staining demonstrated the development of a
cellular layer in the UCP-seeded grafts, which appeared tomature
and thicken after dynamic conditioning (Figure 9A). Although
no new elastin fibers were detected, collagen deposits were
identified within the cellular layer after dynamic conditioning,
as highlighted by the light blue stain. Analysis of CM collected
after static and dynamic conditioning identified the presence
of soluble collagen, which was not detected in unseeded grafts
(Figure 9B). Importantly, we could appreciate a significant
reduction in the Young’s Modulus of UCP-seeded grafts in
comparison to the unseeded control, indicating an increase
in elasticity (Figure 9C). Dynamic conditioning appeared to
further increase elasticity. In concurrence with this, there was a
significant increase in rupture strain in seeded grafts, which was
particularly evident after dynamic conditioning (Figure 9D).
Altogether, these results highlight the ability of UCPs to
engraft and proliferate within the CorMatrix scaffold, changing
the ECM protein content toward an elastic phenotype.
DISCUSSION
Our previous work provided a rationale for the use of human
pericytes from the neonatal heart to engineer clinically
available prosthetic grafts (9, 14). However, isolation of this
promising cell population is reliant upon tissue obtained
during initial palliative surgery or an ad hoc invasive cardiac
biopsy. In search of a more accessible source of pericytes,
we focused on the umbilical cord, which is acknowledged
to contain stromal cells and perivascular cells endowed
with regenerative capacity. We developed a standard
protocol for pericyte isolation, based on immunomagnetic
separation of NG2 positive cells from the explant outgrowth
produced by umbilical arteries. Having confirmed that NG2
positive cells share typical antigenic properties, perivascular
location, and paracrine activities indicative of pericytes, we
demonstrated their ability to promote HUVEC migration
and tube formation. In functional assays, NG2 UPCs
outperformed Wharton’s Jelly-derived MSCs. Finally, we
demonstrated that NG2 UPCs can engraft and grow onto a
CorMatrix graft, changing its mechanical properties toward an
elastic behavior.
The umbilical cord starts to form at about 4 weeks of
pregnancy and usually grows to about 22 inches long at
birth. Previous studies using umbilical artery dissection and
culture selection identified this tissue as a source of perivascular
mesenchymal stromal cells suitable for regenerative medicine
applications. However, only cells that were collected during
early gestation expressed stemness markers and exhibited a
high proliferative potential and multilineage differentiation
capacity compared with full-term counterparts, suggesting
a restriction in regenerative activity of these cells occurs
through gestation (22). Alternatively, the method used may
be not adequate to separate and expand the small number of
progenitors contained within the bulk cell population of a full-
term cord artery. We employed immunomagnetic sorting to
separate NG2 positive cells from colonies outgrowing from the
umbilical artery of full-term neonates, after initial unsuccessful
attempts based on CD34 immunomagnetic selection (14,
15). CD34 is a transmembrane glycoprotein protein typically
expressed by adventitial pericytes; whereas umbilical vessels
do not possess a distinct adventitia (23). Indeed, Schugar et
al. previously demonstrated that CD34 expression may be
restricted to the endothelial layer in the umbilical vessels
(21). Accordingly, in situ immunohistochemistry confirmed the
absence of CD31−/CD34+ pericyte-like cells in umbilical vessels.
Surprisingly, we only identified sporadic staining of NG2 positive
cells within the tissue, whereas Crisan et al. identified a distinct
NG2 positive pericyte layer within the umbilical artery (24). This
result may be due to different methods of tissue processing.
Nevertheless, the study by Crisan et al. indicates that NG2 is a
suitable selection marker for umbilical cord pericytes.
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FIGURE 8 | Analysis of cell engraftment on CorMatrix graft. (A,B) Representative images of cell distribution and viability after conditioning on CorMatrix scaffold. (A)
static conditioning. (B) dynamic conditioning. Cytoplasmic green fluorescence, live (Calcein AM) cells; Nuclear red fluorescence, dead (ethidium homodimer-1) cells.
(C) Cell viability. (D) Cell density (E) Cell proliferation. (F) Representative immunohistochemical images demonstrating NG2 UCP presence in graft. Static = 5 days
static conditioning, dynamic = 5 days static plus 7 days dynamic conditioning. Data represent means (±S.E.M). n = 4 biological replicates. *p < 0.05.
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FIGURE 9 | Analysis of NG2 UCP engineered graft structure and properties. (A) Representative images of hematoxylin and eosin staining (H&E), elastin van Gieson
staining (EVG) and Mallory’s trichrome collagen staining (COL) of NG2 UCP seeded CorMatrix grafts. (B) Quantification of Pro-Collagen 1 a1 in CM. (C) Quantification
of Young’s Modulus. (D) Quantification of rupture strain. Static = 5 days static conditioning, dynamic = 5 days static plus 7 days dynamic conditioning. Data represent
means (±S.E.M). Unseeded n = 3, and seeded n = 4 biological replicates. *p < 0.05 and **p < 0.01.
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Antigenic characterization confirmed that expanded NG2
positive cells resemble bona fide pericytes, therefore we coined
for them the term of NG2 UCPs. Phenotypically, NG2 UCPs
are similar to cardiac and saphenous vein pericytes, except
they moderately express CD146, which is typically not found
in pericytes isolated using CD31−/CD34+ selection (14, 15).
Similarly, they also express stemness markers, rapidly proliferate
in culture to 10 million cells in under 6 weeks and can be induced
to a contractile VSMC phenotype, although we did not detect
acquisition of a mature phenotype, as seen in cardiac pericytes.
Nevertheless, this data suggests that a subfraction of umbilical
cord perivascular cells maintain a progenitor cell phenotype
through gestation.
By analyzing secreted growth factors we aimed to understand
the NG2 UPC angiogenic potential, and how this may change in
response to an oxygen poor environment, such as an avascular
tissue engineered construct (25, 26). In fact, engineered tissues
thicker than 1mm are prone to become necrotic before perfusion
by host-derived microvessels (27, 28). A cell that can adapt
to this environment effectively may be favorable for tissue
engineering. We compared NG2 UCPs to a commercial line
of Wharton’s Jelly MSCs, which are often the focus of cell
therapy and tissue engineering applications (29, 30). NG2 UCPs
remarkably outperformed their comparator regarding the ability
to release SDF-1, VEGF-A, HGF, and MCP-1 under normoxia
and hypoxia, while showing moderately lower levels of ANGPT-
1. Interestingly, this differed quite considerably from cardiac
pericytes, which secreted significantly more VEGF-A, HGF and
ANGPT-2 (14). Using a fibroblast-endothelial cell coculture
assay, we confirmed the superior proangiogenic potential of NG2
UCPs, as highlighted by greater endothelial network formation
induced by their CM and closer contacts with network branches
in comparison with MSCs. This result was comparable to tube
formation data from cardiac pericytes; however, intriguingly the
angiogenic paracrine effect of NG2 UCPs appears superior (14).
Thismay be due to the high secretion of ANGPT-2 seen in cardiac
pericytes, which in the absence of angiogenic stimulation results
in vessel regression (31). Additionally, data indicates that NG2
UCPs may help facilitate the development of a graft endothelial
layer. In animal models of transplanted vascular grafts,
reendothelialization tends to occur through trans-anastomotic
ingrowth, however, in humans this process is much slower and
limited to <2 cm (32, 33). Consequently, this leads to incomplete
endothelial layer formation and thrombotic complications.
Through implementation of a scratch wound migration model
we showed that CM from NG2 UCPs enhanced EC migration,
which may increase efficiency of trans-anastomotic ingrowth.
Furthermore, the proangiogenic properties of NG2 UCPs may
support transmural capillarization, which has been identified as
a more feasible mechanism of reendothelialization in humans
(32). Conversely, saphenous vein pericyte CM do not influence
endothelial migration (15). Together, this data suggests NG2
UCPs may possess superior paracrine endothelial supportive
properties than pericyte populations previously isolated by
our group.
The ECM of native arteries can dynamically remodel through
a tightly regulated balance of matricellular protein production
and MMP activity, whereas this dynamic phenomenon is lost
in acellular grafts, resulting in lack of growth potential and
susceptibility to degradation (34). The main constituents of
vascular ECM are collagens and elastin, which are present in
different proportions according to the type and anatomical
location of the tissue. In fact, the arterial wall is made up of up
to 50% elastin, which provides mechanical integrity and vessel
elasticity (35). Conversely, CorMatrix is made up of 90% collagen,
predominantly collagen type I (36). A lack of elastin synthesis
in tissue engineered vascular grafts has been highlighted as a
major limitation to successful outcomes (37). Noteworthy, we
have shown that NG2 UCPs produce significant amounts of
both collagen and elastin, which suggests that seeding of these
cells may improve mechanical properties of acellular scaffolds.
Naturally, this ECM production must be regulated to ensure
there is minimal risk of pathological remodeling. In accordance
with this, we analyzed MMP presence and activity in isolated
cells. Although general intracellular MMP levels were low in
comparison to TIMPs, we saw significantly increased levels
of extracellular MMP-1. This observation was mirrored by an
increased extracellular collagenase activity, suggesting MMPs
may become activated upon secretion. MMP-1 acts on collagen
type I, the predominant collagen in animal derived ECM such
as CorMatrix, suggesting that NG2 UCPs could degrade and
remodel this material (38).
Finally, we explored the feasibility of engineering a biological
graft by incorporating NG2 UCPs onto CorMatrix. Analysis of
cell distribution demonstrated a largely uniform engraftment,
although some areas where the conduit had been gripped were
sparsely populated and had an increased number of apoptotic
cells. Specifically, there was a drop in viability after dynamic
conditioning. Improvement in physical manipulation of the
scaffold is warranted to maintain cell viability from static to
dynamic conditions. Interestingly, NG2 UCPs demonstrated
organization after stimulation under flow conditions, which may
have important implications for the mechanical properties of
the graft (39). Immunohistochemical staining demonstrated that
NG2 UCPs retain their original phenotype, with the absence of
αSMA suggesting that additional stimuli and/or prolonged shear
stress are required to encourage development of a smooth muscle
layer. Analysis also revealed that the cells form a layer on the
external surface of the CorMatrix scaffold rather than infiltrate
into the matrix. Whilst this lack of infiltration initially looked
concerning, it is not necessarily a poor outcome. The purpose of
cellularizing the exterior surface of the CorMatrix conduit was
to create an adventitial cellular layer capable of recruiting native
vascular cells and repopulating the acellular scaffold through the
therapeutic properties of NG2 UCPs.
No new elastin fibers were detected in the cellularized graft;
however, it is possible that 12 days were not enough for
fiber development. Nonetheless, evidence of scaffold remodeling
was detected through progressive collagen deposition and the
presence of soluble collagen (alpha-1 type I collagen) in the
conditioned medium. Alpha-1 type I collagen is a major
component of collagen type 1; its presence may indicate that
the cells are actively remodeling the collagen in the CorMatrix
scaffold. In accordance with this, we observed a considerable
change in mechanical properties of the graft. Although the
cellularized graft still remained stiffer than native arterial tissue,
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the reduction in Young’s modulus demonstrated a significant
increase in elasticity from the acellular graft (40). Furthermore,
the increase in rupture strain suggests an increased compliance
of the graft, which is essential for normal arterial function (41).
These data demonstrate that the NG2 UCP-engineered graft
possesses significant improvements over acellular CorMatrix,
which is an FDA-approvedmaterial widely used in cardiovascular
reconstructive surgery of pediatric and adult patients.
CONCLUSION
We have demonstrated that a novel population of NG2+
pericytes can be consistently isolated and expanded from
discarded umbilical tissue. The acquired cell population
demonstrates high reproducibility and a homogenous phenotype.
Furthermore, NG2+ pericytes possess specific properties that
make them a desirable candidate for vascular tissue engineering
in patients with CHD. The ability of NG2 UCPs to produce their
own ECM could pave the way to the implementation of clinically
available grafts but also to the manufacture of novel grafts made
of umbilical vascular cells and a native stromal matrix.
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